• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].

作者信息

Limbourg Florian P

机构信息

ESH/DHL Universitäres Hypertoniezentrum/Experimentelle Gefäßmedizin und Transplantationsforschung, Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, D-30625, Hannover, Deutschland.

出版信息

MMW Fortschr Med. 2020 May;162(9):67-69. doi: 10.1007/s15006-020-0483-y.

DOI:10.1007/s15006-020-0483-y
PMID:32405833
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7220578/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac1/7220578/5aa1ef09e004/15006_2020_483_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac1/7220578/7630934586df/15006_2020_483_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac1/7220578/5aa1ef09e004/15006_2020_483_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac1/7220578/7630934586df/15006_2020_483_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fac1/7220578/5aa1ef09e004/15006_2020_483_Fig2_HTML.jpg

相似文献

1
[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].[2019冠状病毒病时期的高血压与肾素-血管紧张素-醛固酮系统抑制——欧洲高血压学会的当前建议。]
MMW Fortschr Med. 2020 May;162(9):67-69. doi: 10.1007/s15006-020-0483-y.
2
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).螺内酯可能提供针对 SARS-CoV-2 的保护：靶向雄激素、血管紧张素转换酶 2（ACE2）和肾素-血管紧张素-醛固酮系统（RAAS）。
Med Hypotheses. 2020 Oct;143:110112. doi: 10.1016/j.mehy.2020.110112. Epub 2020 Jul 16.
3
Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂对无高血压的新冠患者有益吗？
Pharmacol Res. 2020 Sep;159:104959. doi: 10.1016/j.phrs.2020.104959. Epub 2020 Jun 4.
4
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
5
RAAS blockers in hypertension posing a higher risk toward the COVID-19.用于治疗高血压的肾素-血管紧张素-醛固酮系统（RAAS）阻滞剂会增加感染新型冠状病毒肺炎（COVID-19）的风险。
Dermatol Ther. 2020 Jul;33(4):e13501. doi: 10.1111/dth.13501. Epub 2020 Jun 16.
6
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
7
The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic.冠状病毒感染中的肾素-血管紧张素-醛固酮系统——大流行期间的当前思考
J Cardiothorac Vasc Anesth. 2020 Jul;34(7):1717-1719. doi: 10.1053/j.jvca.2020.04.010. Epub 2020 Apr 16.
8
Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.在对COVID-19中的RAS阻断进行快速判断之前的可靠科学依据。
Clin J Am Soc Nephrol. 2020 May 7;15(5):714-716. doi: 10.2215/CJN.03530320. Epub 2020 Mar 27.
9
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.肾素-血管紧张素系统抑制剂对新型冠状病毒肺炎中2019冠状病毒感染及肺损伤的潜在差异影响
Hypertens Res. 2020 Aug;43(8):837-840. doi: 10.1038/s41440-020-0478-1. Epub 2020 May 20.
10
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.

引用本文的文献

1
Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies.肾素-血管紧张素系统抑制剂的使用与高血压COVID-19患者中重症COVID-19风险及死亡率之间的关联：一项观察性研究的荟萃分析
Front Cardiovasc Med. 2021 Apr 26;8:609857. doi: 10.3389/fcvm.2021.609857. eCollection 2021.

本文引用的文献

1
Erratum to: Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence.《高血压、肾素-血管紧张素系统与下呼吸道感染及肺损伤风险：对2019冠状病毒病的影响：欧洲高血压学会2019冠状病毒病特别工作组证据综述》勘误
Cardiovasc Res. 2021 Sep 28;117(11):2394. doi: 10.1093/cvr/cvab224.
2
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
3
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
4
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
5
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.中国武汉因 2019 年冠状病毒病（COVID-19）感染而住院的高血压患者中，肾素-血管紧张素系统抑制剂与严重程度或死亡风险的关系。
JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624.
6
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.肾素-血管紧张素系统阻滞剂与 COVID-19 大流行：目前尚无证据表明应放弃使用肾素-血管紧张素系统阻滞剂。
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
7
COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?新型冠状病毒肺炎与血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂：证据是什么？
JAMA. 2020 May 12;323(18):1769-1770. doi: 10.1001/jama.2020.4812.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.血管紧张素受体阻滞剂可作为治疗 SARS-CoV-2 的候选药物。
Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.
10
2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension.2018年欧洲心脏病学会/欧洲高血压学会动脉高血压管理指南：欧洲心脏病学会动脉高血压管理特别工作组和欧洲高血压学会：欧洲心脏病学会动脉高血压管理特别工作组和欧洲高血压学会。
J Hypertens. 2018 Oct;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940.